Avaliação in silico, in vitro e in vivo da ação esquizonticida sanguínea de compostos aminoquinolínicos
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
With 247 million new cases and 619,000 deaths in 2021, malaria still remains a
public health challenge worldwide. 96% of malaria cases are concentrated in Africa and
Plasmodium falciparum, considered the most prevalent species on the African continent, is
resistant to several antimalarials. The Americas, the Western Pacific, Southeast Asia and the
Eastern Mediterranean, mainly affected by Plasmodium vivax, also present resistance to the
antimalarial drugs used in therapy. The search for new drugs to treat malaria is considered an
emergency and fundamental issue to avoid the current high rates of morbidity and mortality
from the disease, since there is an increasing development and dissemination of parasites
resistant to conventional antimalarials. Among antimalarial medications, those belonging to
the aminoquinoline class act by inhibiting the polymerization of hemoglobin into hemozoin
during the parasite's sexual life cycle. This study aims to evaluate the antimalarial potential of
16 new synthetic aminoquinoline compounds. The 16 new synthesized drugs were evaluated
for their pharmacokinetic, physical-chemical properties, in vitro cytotoxicity activity and
antiplasmodial activity. The most promising in vitro studies were then evaluated in an animal
model of malaria infection.The pharmacokinetic results suggested good absorption and oral
bioavailability for the tested molecules. For the most promising molecule, compound 9,
docking molecular studies were carried out, demonstrating affinity for the receptors of the
parasitophorous vacuole of the parasite, suggesting a mechanism of action similar to that of
chloroquine. Satisfactory results were found for compound 9 for in vitro antiplasmodial
activity of IC50 (0.44 µM/ml), CC50 (>100 µM/ml) and in vitro selectivity index data for
antiplasmodial activity of 226 (standard drug chloroquine obtained 152). In vivo tests for
compound 9 indicated good inhibition of parasite multiplication up to the tenth day of
infection (31.02%). The interaction with ferriprotoporphyrin complex was investigated by
UV-Vis spectrophotometric titration and its result was comparatively similar to that of
chloroquine (Log K of the compound = 4.66, Log K of chloroquine = 4.97), suggesting this
probable mechanism of action. Biochemical data did not demonstrate toxicity for the murine
model in relation to the doses tested (15 mg/kg and 50 mg/kg). In conclusion, molecules
derived from the aminoquinoline ring, especially compound 9, show promise for future
studies aimed at therapeutic renewal, which is so essential for the control of malaria.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

